Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Jonathan Brody
  • Jordan Winter
  • Dan Dixon
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7095-8



HuR/ELAV1 is an RNA-binding protein and a member of the embryonic lethal abnormal vision (ELAV) protein family. The protein is ubiquitously expressed in normal tissues and posttranscriptionally regulates mRNA targets (numbering in the thousands) with AU-rich elements (ARE). Upon acute stress, activated HuR/ELAV1 moves from the nucleus to the cytoplasm with its mRNA cargo and affects gene expression of its targets by influencing mRNA stability or facilitating protein translation. Cancer cells exploit HuR/ELAV1 biology by upregulating the HuR/ELAV1 pro-survival network (e.g., anti-apoptosis, DNA damage repair, cell cycle progression, and other tumorigenic pathways), particularly in response to acute stressors like hypoxia, nutrient deprivation, or chemotherapy. Clinicopathologic studies in different cancer types demonstrate that increased cytoplasmic expression of HuR/ELAV1 is associated with aggressive pathologic features and poor prognosis.



Acute Stress Nuclear Pore Complex Amino Acid Deprivation Trail Death Receptor Aggressive Pathologic Feature 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Abdelmohsen K, Gorospe M (2010) Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 1(2):214–229CrossRefPubMedGoogle Scholar
  2. Brody JR, Gonye GE (2011) HuR’s role in gemcitabine efficacy: an exception or opportunity? Wiley Interdiscip Rev RNA 2(3):435–444CrossRefPubMedGoogle Scholar
  3. Lopez de Silanes I, Lal A, Gorospe M (2005) HuR: post-transcriptional paths to malignancy. RNA Biol 2(1):11–13CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of SurgeryThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Cancer BiologyUniversity of Kansas Medical CenterKansas CityUSA